Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.

Publication ,  Journal Article
Safford, SD; Goyeau, D; Freemerman, AJ; Bentley, R; Everett, ML; Grundy, PE; Skinner, MA
Published in: Ann Surg Oncol
March 2003

BACKGROUND: The aim of this study was to more precisely map the region of 16q loss of heterozygosity (LOH) in Wilms' tumors and to examine the expression of putative tumor suppressor. METHODS: We performed polymerase chain reaction-based LOH analysis on the 185 sample pairs from 21 to 80 megabases (Mb) on chromosome 16q. Expression of two candidate tumor suppressor genes located within the identified consensus region of 16q LOH was examined by immunohistochemistry. RESULTS: We identified 16q LOH in 7 (4%) of 185 Wilms' tumors not previously thought to demonstrate such genetic loss. The smallest common region of genetic loss was located between 67.3 and 74.0 Mb on chromosome 16. Within this 6.7-Mb region, there reside only three recognized tumor suppressor genes: E-cadherin, P-cadherin, and E2F4. E-cadherin demonstrates statistically significantly reduced expression in Wilms' tumors with 16q LOH. CONCLUSIONS: We have localized the consensus region of 16q LOH in Wilms' tumor to a 6.7-Mb locus and have identified three candidate Wilms' tumor suppressor genes within this narrowed region. Our data support E-cadherin as a candidate tumor suppressor gene in Wilms' tumor; however, further studies are needed to definitively prove its role as the tumor suppressor gene associated with 16q LOH.

Duke Scholars

Published In

Ann Surg Oncol

DOI

ISSN

1068-9265

Publication Date

March 2003

Volume

10

Issue

2

Start / End Page

136 / 143

Location

United States

Related Subject Headings

  • Wilms Tumor
  • Statistics, Nonparametric
  • Polymerase Chain Reaction
  • Oncology & Carcinogenesis
  • Microsatellite Repeats
  • Loss of Heterozygosity
  • Kidney Neoplasms
  • Immunoenzyme Techniques
  • Humans
  • Genetic Markers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Safford, S. D., Goyeau, D., Freemerman, A. J., Bentley, R., Everett, M. L., Grundy, P. E., & Skinner, M. A. (2003). Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases. Ann Surg Oncol, 10(2), 136–143. https://doi.org/10.1245/aso.2003.03.038
Safford, Shawn D., Dominique Goyeau, Alex J. Freemerman, Rex Bentley, Mary Lou Everett, Paul E. Grundy, and Michael A. Skinner. “Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.Ann Surg Oncol 10, no. 2 (March 2003): 136–43. https://doi.org/10.1245/aso.2003.03.038.
Safford SD, Goyeau D, Freemerman AJ, Bentley R, Everett ML, Grundy PE, et al. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases. Ann Surg Oncol. 2003 Mar;10(2):136–43.
Safford, Shawn D., et al. “Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.Ann Surg Oncol, vol. 10, no. 2, Mar. 2003, pp. 136–43. Pubmed, doi:10.1245/aso.2003.03.038.
Safford SD, Goyeau D, Freemerman AJ, Bentley R, Everett ML, Grundy PE, Skinner MA. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases. Ann Surg Oncol. 2003 Mar;10(2):136–143.
Journal cover image

Published In

Ann Surg Oncol

DOI

ISSN

1068-9265

Publication Date

March 2003

Volume

10

Issue

2

Start / End Page

136 / 143

Location

United States

Related Subject Headings

  • Wilms Tumor
  • Statistics, Nonparametric
  • Polymerase Chain Reaction
  • Oncology & Carcinogenesis
  • Microsatellite Repeats
  • Loss of Heterozygosity
  • Kidney Neoplasms
  • Immunoenzyme Techniques
  • Humans
  • Genetic Markers